Antengene (HKG:6996) will establish a dedicated artificial intelligence department by increasing its investment in AI-driven drug discovery and AI-focused R&D efforts.
The initiative includes deploying DeepSeek to expedite the development of its next-generation proprietary T-cell engager (TCE) pipeline, which features a steric hindrance-masking technology.
The drugmaker plans to leverage targeted algorithms and AI-driven data mining to perform cross-database, multi-omics analyses for drug discovery and development, a Wednesday bourse filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。